Medical Devices Industry Reports Vagus Nerve Stimulators Market Size, Share, Analys | Page 2

REPORT DESCRIPTION
Vagus Nerve Stimulators Market – Overview
According to the data published by National Institute of Mental Health in 2016, an estimated 16.2 million adults
in the U.S. had at least one major depressive episode. This number represented 6.7% of all U.S. adults. According
to the same source the prevalence of major depressive episode was higher among adult females (8.5%) compared
to males (4.8%) and the prevalence of adults with a major depressive episode was highest among individuals aged
18-25 (10.9%).
Approval and launch of novel products in market is also expected to support the vagus nerve stimulators market
growth over the forecast period. For instance, in June 2017, electroCore, Inc. received the U.S. Food and Drug
Administration (FDA) 510(k) clearance to market a newer version of gammaCore (non-invasive vagus nerve
stimulator) – the gammaCore-S – for acute treatment of pain associated with episodic cluster headache (eCH) in
adult patients.
Furthermore, in February 2019, the U.S. Centers for Medicare & Medicaid Services (CMS) finalized its national
coverage determination (NCD) for the LivaNova Plc.’s vagus nerve stimulation therapy (VNS Therapy) System
for treatment-resistant depression (TRD). Such favorable reimbursements for VNS devices for depression
treatment is also expected to increase its adoption and drive vagus nerve stimulators market growth